
    
      This is a Phase 2a, Open-Label, Single-Arm Study to Investigate the Safety and Efficacy of
      ATI-450 for the Maintenance of Remission in Patients with Cryopyrin-Associated Periodic
      Syndrome (CAPS) Previously Managed with Anti-IL-1 Therapy. The study will consist of up to an
      8-week screening period, a 12-week treatment period, and a 4-week safety follow-up period.
      The total duration of the study for patients remaining until their final follow-up assessment
      will be up to 24 weeks.
    
  